A potent and selective peptide blocker of the Kv1.3 channel: Prediction from free-energy simulations and experimental confirmation

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Rashid, M Harunur ^a   Heinzelmann, Germano ^a   Huq, Redwan ^b   Tajhya, Rajeev B ^b   Chang, Shih Chieh ^c   Chhabra, Sandeep ^c   Pennington, Michael W ^d   Beeton, Christine ^b   Norton, Raymond S ^c   Kuyucak, Serdar ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MONASH UNIVERSITY   (Australia)

^d Peptides International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.1; POTASSIUM CHANNEL KV1.3; SHK PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG BINDING; DRUG SELECTIVITY; FIBROBLAST; FREE ENERGY PERTUBATION; MATHEMATICAL COMPUTING; MOLECULAR DYNAMICS; MOUSE; MUTATION; NONHUMAN; PREDICTION; RAT; SIMULATION; T LYMPHOCYTE; THERMODYNAMIC INTEGRATION; WHOLE CELL PATCH CLAMP;

AMINO ACID SUBSTITUTION; ANIMALS; AUTOIMMUNE DISEASES; CELL LINE; COMPUTER SIMULATION; FEMALE; KV1.3 POTASSIUM CHANNEL; MICE; MODELS, MOLECULAR; MUTATION, MISSENSE; PEPTIDES; POTASSIUM CHANNEL BLOCKERS; RATS; RATS, INBRED LEW; THERMODYNAMICS;

EID: 84892388463     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078712     Document Type: Article

References (33)

1. + channel in effector memory T cells as new target for MS. J Clin Invest 111: 1703-1713.
2. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, et al. (2006) Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103(46): 17414-17419.
3. Castaneda O, Sotolongo V, Amor AM, Stocklin R, Anderson AJ, et al. (1995) Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus. Toxicon 33: 603-613.
4. Norton RS, Pennington MW, Wulff H (2004) Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases. Curr Med Chem 11: 3041-3052.
5. Beeton C, Pennington MW, Norton RS (2011) Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflammation & Allergy Drug Targets 10: 313-321.
6. Kalman K, Pennington MW, Lanigan MD, Nguyen A, Rauer H, et al. (1998) ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem 273: 32697-32707.
7. Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, et al. (2012) Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon 59: 529-546.
8. Beeton C, Wulff H, Singh S, Botsko S, Crossley G, et al. (2003) A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem 278: 9928-9937.
9. Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, et al. (2005) Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Molec Pharmacol 67: 1369-1381.
10. Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, et al. (2009) Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Molec Pharmacol 75: 762-773.
11. Rashid MH, Kuyucak S (2012) Affinity and selectivity of ShK toxin for the Kv1 potassium channels from free energy simulations. J Phys Chem B 116: 4812-4822.
12. Pennington MW, Rashid MH, Tajhya RB, Beeton C, Kuyucak S, et al. (2012) A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3. FEBS Letters 586: 3996-4001.
13. Pennington MW, Mahnir VM, Khaytin I, Zaydenberg I, Byrnes ME, et al. (1996) An essential binding surface for ShK toxin interaction with rat brain potassium channels. Biochemistry 35: 16407-16411.
14. Rauer H, Pennington M, Cahalan M, Chandy KG (1999) Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin. J Biol Chem 274: 21885-21892.
15. + channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45: 1227-1234.
16. + T lymphocytes: green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nat Medicine 5: 843-847.
17. Beeton C, Chandy KG (2007) Induction and monitoring of adoptive delayed-type hypersensitivity in rats. J Vis Exp (8): 325.
18. Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, et al. (2008) Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 29: 602-614.
19. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 98: 13942-13947.
20. Chang SC, Galea CA, Leung EW, Tajhya RB, Beeton C, et al. (2012) Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria. Toxicon 60: 840-850.
21. Beeton C, Chandy KG (2007) Induction and monitoring of active delayed type hypersensitivity (DTH) in rats. J Vis Exp (6):237.
22. Tudor JE, Pallaghy PK, Pennington MW, Norton RS (1996) Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone. Nat Struct Biol 3: 317-320.
23. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38.
24. Tudor JE, Pennington MW, Norton RS (1998) Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin. Eur J Biochem 251: 133-141.
25. Dominguez C, Boelens R, Bonvin AM (2003) HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc 125: 1731-1737.
26. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.
27. MacKerell AD, Bashford D, Bellott RL, Dunbrack RLJ, Evanseck JD, et al. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102: 3586-3616.
28. MacKerell AD Jr, Feig M, Brooks CL 3rd (2004) Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem 25: 1400-1415.
29. Beveridge DL, DiCapua FM (1989) Free energy via molecular simulation: applications to chemical and biomolecular systems. Annu Rev Biophys Biophys Chem 18: 431-492.
30. Zacharias M, Straatsma TP, McCammon JA (1994) Separation-sifted scaling, a new scaling method for Lennard-Jones interactions in thermodynamic integration. J Chem Phys 100: 9025-9031.
31. Heinzelmann G, Bastug T, Kuyucak S (2011) Free energy simulations of ligand binding to the aspartate transporter GltPh. Biophys J 101: 2380-2388.
32. Chen PC, Kuyucak S (2011) Accurate determination of the binding free energy for KcsA-charybdotoxin complex from the potential of mean force calculations with restraints. Biophys J 100: 2466-2474.
33. Kumar S, Bouzida D, Swensen RH, Kollman PA, Rosenberg JM (1992) The weighted histogram analysis method for free-energy calculations on biomolecules. J Comput Chem 13: 1011-1021.